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Background: This article provides a framework for disentangling the concept of participation, with emphasis on
participation in genomic medicine. We have derived seven ‘dimensions’ of participation that are most frequently
invoked in the extensive, heterogeneous literature on participation. To exemplify these dimensions, we use material
from a database of 102 contemporary cases of participation, and focus here on cases specific to science and
medicine. We describe the stakes of public participation in biomedical research, with a focus on genomic medicine
and lay out the seven dimensions.
Discussion: We single out five cases of participation that have particular relevance to the field of genomic
medicine, we apply the seven dimensions to show how we can differentiate among forms of participation within
this domain.
Summary: We conclude with some provocations to researchers and some recommendations for taking variation in
participation more seriously.Background
Public participation is a matter of growing importance in
the biosciences, but we lack a comprehensive framework
for making sense of the many forms that it takes. Is par-
ticipation in a newborn-screening program the same thing
as joining 23andMe? Is patient activism to steer research
funding the same thing as a movement-run community
health clinic? Is participation in a bone marrow registry
the same thing as participation in a clinical trial? Is the ac-
tive participation of parents in their autistic child’s therapy
the same as the rejection of medical authority in the deci-
sion not to vaccinate? All of these things are labeled 'pub-
lic participation' in biomedicine, yet they capture many
different types of relationships between a lay public, doc-
tors or researchers, governments and other stakeholders.
The stakes of public participation for biomedicine are
high, yet we lack an adequate language for distinguishing
among the variety of entities, practices, and relationships
that are designated as participatory and for evaluating
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article, unless otherwise stated.This article provides a framework for disentangling the
concept of participation. Based on the extensive and het-
erogeneous theoretical and practical literature, we have
derived seven 'dimensions' of participation that are most
frequently invoked to explain its function and goals. In
order to exemplify these dimensions, we use material
drawn from a database of 102 contemporary cases of par-
ticipation - focusing for this article on those cases that are
specific to science, technology and medicine. In this back-
ground section, we describe some of the stakes of the
growing trend of public participation in biomedical re-
search, with a particular focus on genomic medicine, lay
out the seven dimensions and describe how our larger re-
search project approaches the problem. In the discussion
section we single out five cases of participation that have
particular relevance to the field of genomic medicine, and
we apply the framework to show how we can differentiate
among forms of participation within this domain. In the
summary we conclude with some provocations to re-
searchers and some recommendations for taking variation
in participation more seriously.Public participation in biomedicine
The participation of members of the public as research
subjects and also as patients has long been a sine quaentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and medical researchers have preferred research subjects
to remain 'subject' to their direction and control, not
'subjects' in the sense of people who 'talk back' to ex-
perts and insist on representing or pursuing their own
interests. The reaction of the biomedical research estab-
lishment to such vocal and organized forms of public
participation has ranged from paternalistic to hostile,
seeing challenges to the authority of the establishment
as attacks on the integrity of scientific research and
medical practice. And thus the best known historical ex-
amples of this public participation - such as the women’s
health movement, the Black Panther Party’s free medical
clinics, and AIDS activism - have involved resistance to
the biomedical establishment [1-4].
However, in recent decades public participation has
lost much of its adversarial edge to become a key, legit-
imating idiom of institutions across the spectrum of so-
ciety. Rather than asserting a separation from the public,
government, civil society, and even business organiza-
tions now 'engage', 'solicit advice from', and 'consult
with' the public in patterns of authority that emphasize
shared responsibility over top-down government [5-10].
Sometimes these examples include grounded, practical
attempts at participation, while in other cases they are
more rhetorical or theoretical assertions. Conversely,
cases of public exclusion, secrecy, and institutional au-
tonomy are occasions for public suspicion and resist-
ance. The biomedical research establishment has joined
this trend to see public participation as good [11-16]. In
the US, the NIH, long resistant to public 'interference',
has come to acknowledge the role of disease advocates
(for example, in attracting research support, developing
drugs and therapies, and clinical trials) [17]. In France,
the Muscular Dystrophy Association (AFM), has funded
a substantial portion of genetics research [18]. And thus,
even more than providing the idiom of legitimacy for
contemporary institutions, public participation can at
times fill in where the state (or market) is failing to sup-
ply crucial research goods.
In the past few years, scientific researchers have begun
to take an even more active and creative approach to
public participation, using the ubiquity of the Internet
and its interactive affordances to solve a nexus of prob-
lems [19-24]. For example, biochemists studying protein
folding have teamed up with computer scientists to build
an online game, Fold It, that invites public users to
compete in devising solutions to protein folding prob-
lems that are then used to 'train' computers to improve
their protein structure algorithms [25-28]. The website
Zooniverse is a platform where scientists studying prob-
lems as diverse as galaxy formation, bat vocalization,
and cancer can recruit the public to aid in massive,
labor-intensive data coding efforts [29-32]. Off-line,public health researchers have spearheaded participatory
research as a means to recruit from hard-to-reach popu-
lations, prioritize communities’ own health concerns,
and to develop interventions that rely on social capital
and peer influence rather than top down messages or
coercive rules to improve health [33].
The well known direct-to-consumer genetic testing
company 23andMe has organized public participation to
solve a knot of problems facing genetics researchers. By
inviting users to pay (currently $99) for a SNP-chip-
based genetic test and then answer online surveys about
their health, traits, and ancestry, 23andMe has been able
get about 400,000 people to pay to provide the company
with valuable genetic and phenotypic data. The online
interface allows 23andMe to stay connected with partici-
pants, introducing new studies and re-consenting them
as necessary. 23andMe seems to be solving some of the
ongoing cultural problems genetics has faced through
fears of determinism, eugenics, privacy invasion, and dis-
crimination. Its friendly interface, cultivation of well-
informed participants, fun 'see for yourself' ethos, and
multiple choice points for users to participate and dis-
close or not are all geared toward building senses of self-
empowerment and trust and allaying fearful associations
[34,35]. The traditional biomedical establishment has
been duly skeptical of 23andMe’s participatory ethos,
criticizing direct access to genetic data as dangerous to
participants and potentially exploitative [36-41].
Thus, the stakes of public participation for biomedical
research are high, both for these positive possibilities
and for potential dangers (we need only think of vaccine
skepticism and desperate patients’ pursuit of unvalidated
treatments). But what is participation? Many different
definitions have been offered, depending on the practical
domain, or theoretical tradition. We begin with a defin-
ition from Bucchi and Neresini that was intended for the
domain of science, technology and medicine: 'the diver-
sified set of situations and activities, more or less spon-
taneous, organized and structured, whereby nonexperts
become involved, and provide their own input to, agenda
setting, decision-making, policy forming, and knowledge
production processes regarding science (449)' [42]. A
key feature of this definition - which is essential to our
selection of case studies as well - is that participation in-
volves influence of some broad public on a relatively
closed institutional locus of power and decision making
that is not exhausted by market, labor, or electoral rela-
tions. Thus, purchasing, working, or voting are not in
themselves participatory but might be the point of de-
parture for a participatory workplace, 'pro-sumption', or
participatory democracy. The word 'participation' is
often used in a very general sense to mean something
more like the diversity or representativity of a population
(as in 'participation in medical research by minorities')
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a defined activity (for example, 'voter participation' in an
election), but these uses of the word do not rise to the
level of participation we analyze here.
However, this basic definition of public participation
conceals the variety of ways that participatory relation-
ships can be organized. For example, Facebook is often
identified as a participatory technology par excellence
because it has over a billion users to whom it offers pro-
cesses of communication and planning, information
sharing, and interest promotion that were previously
controlled by centralized media outlets. However, it
looks much different as a participatory endeavor to other
projects also labeled participatory, and we provide a
framework here for understanding why.
Disentangling participation
Our approach to disentangling participation is con-
cerned both with the mechanics and structure of par-
ticipation and with the way individuals talk about,
experience or argue for or against it, both as a practice
and as a theoretical problem. Our starting assumption is
that there is a wide diversity of practices that get called
participation, and that we need multiple cases from dif-
ferent domains in order to understand the nature of this
variation. To accomplish this we employ two methods:
one is an extensive investigation in the published litera-
ture, both contemporary and historical, to understand
how the concept of participation has been handled in
the past, which provides the warrant for our choice of
dimensions. Existing frameworks [5,13,43-48] for under-
standing participation tend to be very domain-specific,
from medicine to worker participation to art, but we
have sought to distill commonalities across these mul-
tiple domains, in part to explore how much participation
is or is not tied to specific grounded instances of it. As
such, our reading of this literature was not confined to
any particular discipline, and reveals that there are mul-
tiple non-overlapping places where participation has
been explored at both a theoretical level and in terms of
practical implementation. The most robust literature
comes from the domains of 1) political theory and par-
ticipatory democracy; 2) worker participation; 3) public
administration and; 4) international development. Other
domains such as art, architecture, urban planning, co-
operative and socialist planning, management, participa-
tory design and cultural studies - as well as approaches
in medicine, healthcare and science - corroborate our
choices. In the next section we discuss these seven di-
mensions in more detail, and describe how they relate to
science and medicine.
The other aspect is the creation of an extensive data-
base of structured case studies, conducted through
ethnographic observation, interview and/or analysis ofpublic documents. As of this writing, 102 case studies
have been completed about instances of participation:
groups, organizations, movements or projects organized
in order to facilitate participation of some kind, and to
benefit from it. The purpose of these case studies is
more comparative than casuistic - we use the data col-
lected to evaluate how participation is implemented in
each case, and in order to exemplify different configura-
tions of participation. Our approach is naturalistic in the
sense that we choose any cases 'in the wild' that either
explicitly claim to be participatory or are labeled as such
by others. To date, our only limiting criterion for this set
of cases was that they all involve the use of the Internet
or other information and communication technologies.
Each case study answers 32 structured questions (de-
scribed in [49]), and is based on public records, websites,
news articles, discussions, and interviews with key par-
ticipants. The cases were drawn from a range of do-
mains: Free/Open Source Software (FOSS) (19); social
networking (14); science/engineering (14); culture indus-
try/other (13); activism (10); education (7); citizen jour-
nalism (7); social entrepreneurialism (6); craft/DIY/
consumer goods (5); games/persistent worlds (4); and
forum/mailing list (4). Figure 1 provides an example and
see [50] for more details.
These two approaches were combined by using the
seven dimensions to evaluate each of the 102 cases (6 to
7 researchers evaluated a subset of the cases, resulting in
3 to 4 evaluations for each case). By doing so we gener-
ate a 'consensus score' for each case that represents the
expert analysis of our team about the degree to which
each case includes or excludes each of the dimensions.
Each case therefore has a seven-dimensional 'signature'
that we can use to compare the cases and to look for
patterns that represent different modes of participation
(see Figure 2 for an example). In terms of other meth-
odological approaches, ours shares some similarity with
so-called 'grounded theory' and 'fuzzy-set' social science
[51-53]. However, our intention in this paper is primarily
descriptive and aimed at an empirical specification of
the meanings of participation; we suggest some future
directions for research in the summary.
Educative dividend
Perhaps the most commonly remarked upon, and most
important aspect of participation is its educative poten-
tial. Education here can mean both the simple acquisi-
tion of knowledge and skills, but also the knowledge of
how to participate better - civic virtue. The cultivation
of civic virtue has a grand tradition, including the works
of Machiavelli, Locke, Rousseau, Mill, De Tocqueville,
the 19th century French socialists like Proudhon and
Fourier, and the 20th century British socialists like GDH
Cole. Civic virtue is necessary in order for participation
Figure 1 Sample cases of participation. Sample case study from the 'Comparative Analysis and Study Environment' (CASE) software framework.
At left, the basic information for one case (9 of 32 fields shown); at right, a listing of available cases with selected criteria for filtering/sorting (13
of 102 cases shown).
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clearly difficult to instill such virtues in (all) individuals
in the first place. Many such theories, therefore, rely on
the idea that participation itself leads to greater civic
virtue: that one learns to participate by participating.
Carole Pateman’s 1976 classic Participation and Demo-
cratic Theory explores the history of this theory; accord-
ing to Pateman, democratic theories of the early 20th
century abandoned a participatory theory because the
sociological evidence concerning engagement and apathy
led them to assert that most people are constitutionally
incapable of, or simply uninterested in, participating.
Participatory theory, by contrast, offers a different ex-
planation - that apathy or lack of engagement follow
from a lack of participation, rather than preceding it. If
there were more opportunities for participation, individ-
uals would cultivate those skills to a greater extent and
ultimately develop civic virtue and participate to a
greater extent. Pateman suggests that the 'patterns of au-
thority' across society (at work, at home and locally as
well as nationally) have an effect on this cultivation
[54-56].
In science and medicine, education is very often a key
good presumed to result from participation: whether
that be knowledge of self or knowledge about the world,
more participation reduces the ‘knowledge’ deficit of cit-
izens often decried in discussions of scientific literacy
[57,58]. Although it should be clear from both the ex-
perience of practitioners and the curricular expectations
that 'learning by doing' is key to becoming a better sci-
entist, it is rare to hear it suggested that non-expertsshould actually be encouraged to enter science this way.
'DIY' science and some forms of citizen science are
therefore often met with concern for exactly this reason
[59,60].
Goals versus tasks
Participation in decision-making is among the most in-
tuitive senses of what it means to effectively participate
in something: the possibility of affecting the setting of
goals not merely the accomplishment of tasks oriented
towards those goals. From worker participation to par-
ticipation in development planning to participatory dem-
ocracy, the move has always been ‘upward’ towards
increasing involvement in the management, agenda and
operations of any project or organization [43-45]. At the
same time, bureaucracy and the division of labor provide
a countervailing ‘downward’ force that has worked to
manage scale, equity, and the distribution of power,
often restricting the sense of participation [61-64]. Clas-
sic labor analyses (both Marxist and non) have noted the
disempowering aspects of this distinction [65,66].
A key aspect of this dimension therefore has to do
with the structuring of participation, and the develop-
ment of affordances and metrics (see the 'Metrics of
participation' section below) that enable participation,
make it easier to do, or provide feedback on the effects
of participation. If participation is too highly 'engi-
neered', it is likely to seem inauthentic and the goals will
appear inaccessible to the participant. Critiques of par-
ticipation in international development [67] and science
studies [68] often point out that when participation is
Figure 2 Sample evaluation grid. Sample evaluation grid from the 'Comparative Analysis and Study Environment' (CASE) software framework.
For each question 1 through 7 the circles display researchers’ collective consensus score (+/−) of each case (for example, Q3 concerns control
and ownership of resources). In the center of each circle is the total number of evaluators; the pie chart shows the degree of consensus - all
positive (green), mixed and all negative (red) (yellow indicates a sub-question that is not applicable); a black outline represents interpretations or
comments added by the evaluator. Cases can be re-sorted by question (Q2.1 and Q3.1 are sub-questions).
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who know how to work the system (but lack ‘civic
virtue’). However, it is also possible for participation to
appear too open and unstructured, leaving no certainty
about how to participate, or relying on extensive pre-
existing experience or knowledge in order to do so, as is
often the case in free software projects.
In science and medicine, decision-making can refer to
multiple domains: in medicine, participation in the decision-
making between a doctor and patient [12,15,69] or par-
ticipation in the design of a clinical trial or research
agenda [18,70,71]; in science it can mean participation
in the design of research, or involvement in the general
societal goals and impacts of research. Even strictly
amongst scientific researchers, the participation in 'goals'is often the province of only those most advanced in their
research careers - and it is a mark of prestige to become
the researcher who can set the agenda for research. Much
research has recently investigated how agendas are set in
response to social and political concerns [72-75].
Control and ownership of resources
A third and key dimension of participation is the defin-
ition and control of resources produced. 'Resource' has a
deliberately tangible sound to it, but many cases of partici-
pation may not produce anything tangible or circulatable.
Building a barn, voting on a government, or creating a
local budget all imply different meanings of the term 're-
source' and in each case its production, distribution and
disposition will differ. In many contemporary cases, it is
Kelty and Panofsky Genome Medicine 2014, 6:8 Page 6 of 14
http://genomemedicine.com/content/6/1/8intellectual property and contract law that govern the re-
sources in question, and so there is often a concrete legal
locus to the resources produced by participation [76,77].
Additionally, more than one resource may be at stake in
any given case of participation. One such resource might,
for example, be the educative dividend described above -
tangible acquisition of skills by an individual [78] - while
for the entity enabling it the resource is data, information
or materials donated by the participant. Clinical trials are
a clear example of this duality: health, treatment or medi-
cine is the resource for the patient, but data and informa-
tion comprise the resource for the researcher [70,71].
Identifying the resource is a necessary step preliminary to
defining how it is made available - individually, collectively
or in some other arrangement.
Contemporary participation in the 'information age' is
clearly different from prior experience, insofar as infor-
mation production is a much more common activity
across all domains, and such information has been given
value, often monetary value, in new and experimental
forms - one need only consider the conflicted story of
gene patents for instance. Nonetheless, it helps to think
of 'resources' generally in this context because informa-
tion and information resources are neither new, nor is
their value - but the scale, mode of circulation and 'tan-
gibility' (or ‘objectivity’ perhaps) of such resources are
no doubt taking new and different forms.
Exit…
A classic in economic analysis, Albert O Hirschmann’s
Exit, Voice and Loyalty explored a theory of loyalty in re-
sponse to decline in organizations by asking when con-
sumers (or voters) choose to respond with exit and
when they choose voice [79]. Exit refers to the act of
switching to a competitor (as in the case of competing
products), or dropping out of a market or a political
sphere altogether. Hirschman’s presentation of exit and
voice is not explicitly figured as a theory of participation,
but as one of loyalty. It contains, however, a key feature
of participation rarely remarked on - its character as a
voluntary activity. Almost no situations outright prevent
exit (indentured labor contracts or slavery might be such
cases), but many can make it difficult, costly, dangerous
or threatening to do so (as in the case of clientelism in
politics, or perhaps a loss of health effects by failing to
complete a clinical trial). Loss of reputation, social ties
and potentially the threat of retribution can all be ad-
verse correlates with the value of participation. And key
to such concerns in the contemporary era is, again, the
disposition of resources, that is to say, 'can you take
them with you' if you exit?
Exit, conceived in terms of medical or scientific activity,
raises complicated issues about paternalism, freedom of
choice and responsibility. Patients in clinical trial treatmentregimens are often not at liberty to exit without some kind
of loss (access to medicine and medical treatment princi-
pally), even though it is a principle of human subjects pro-
tection that individuals be guaranteed the right to cease
participation at any time. Participation in scientific research
might be suitably voluntary, but exit might still come with
penalties - loss of data, loss of access to a network, or other
such resources produced through the act of participation.
… and Voice
Hirschman’s alternative - 'voice' - was meant to capture
the tension between loyalty and defection [79]. What
were the conditions, he asked, in which a consumer or
voter was moved to complain (or campaign) rather than
switch? Indeed, voice is generally treated as one of the
most, if not the most, central capacities for participation
in democracy - from the Greek Agora to public coffee
house and the New England town hall meeting [80,81].
The expansion of voice by the Internet is often given as
one reason for its 'democratic' nature; conversely, it is
also suspected of producing echo chambers and 'bubbles'
that limit the effects of participation [82,83].
From the perspective of a theory of participation, how-
ever, it is the effectiveness of these forms that matters:
does feedback register, and if so how? Is it akin to par-
ticipation in goals, not just in tasks? And are participants
able to monitor when their feedback is being heard and
acted upon? Is it structured in such a way to be influen-
tial or merely to provide the appearance of influence?
Additionally, for voice to be effective, there can be no
adverse effects from speaking up, no punitive effects or
retribution for doing so.
Patient advocacy groups would appear to be the most
obvious form of voice in recent history, from AIDS ac-
tivism to those arguing for access to medicine, or re-
search on neglected diseases to the activists in the
vaccine and autism controversy, a key reason to partici-
pate in many different kinds of public projects is to
'make your voice heard' whether conceived of as the ex-
ercise of voice in a public sphere, or participation in
interest group politics.
Metrics of participation
A key aspect of theories of participation is a consistent
concern with the collective (rather than merely the indi-
vidual) experience of participation (hence the adjective
‘civic’ rather than personal or private virtue). But rarely
do these theories explain how individuals can witness or
understand the effect of participation. Metrics or signs
of participation can model the outcome of increased par-
ticipation, or allow an individual to monitor (to varying
degrees of detail), his or her contribution to something,
and its effects. Such metrics can range from the simple
tally of votes to more complex accounting and audit of
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feedback and interaction, as in the classical forms of ap-
prenticeship or mentoring. The rise of statistics and poll-
ing as technologies of collective representation has
played and continues to play a central role in making
such participation visible [84-90]. Among all the dimen-
sions of participation, this is perhaps the least often to
be explicitly named, but the most likely to produce the
experience of linking the individual and the collective
experience together in meaningful ways.
It must also be noted that, in the age of 'big data', it
makes a difference which metrics are available to partici-
pants and when; every computer-enabled service keeps
data of some kind, and large corporations like Facebook
or Google keep massive amounts - but very little of it is
accessible outside of the corporation, sometimes for stra-
tegic reasons, sometimes due to concerns about privacy,
and sometimes simply because it is not perceived as rele-
vant or meaningful data. Metrics meaningful to participa-
tion are evidently those that participants can see, and
perhaps even manipulate. Medical data are obviously of a
different order than other kinds of data - hemmed in by
regulations and concerns about privacy, public health and
individual safety. 'Metrics' then are often of a kind that
represent general trends, rather than revealing information
about individuals. Nonetheless, it is often necessary to
provide such feedback in the service of producing an ex-
perience that is collective in nature, rather than individual.
Subjective, communicative experience of participation
Lastly, participation is fundamentally a collective experi-
ence amongst individuals - and often participation is
understood as a convivial, face-to-face and affective ex-
perience amongst peers - as opposed to anonymous, dis-
connected or rationalized intercourse amongst strangers
(for example, in a market). As a result, many theories of
participation assume that individuals will have or will de-
velop a method of experiencing participation as a collect-
ive experience, somewhat like Durkheim’s notion of
'collective effervescence' [91]. This includes a capacity for
communication amongst members of the organized public
as they participate, and perhaps also an affective language
or relationship that develops - commitment, frustration,
anger, pleasure, satisfaction. Restricting or deliberately sev-
ering such ties has the effect of making the experience
seem less participatory, even if the functional outcome is
the same. Theories of participation often reference these
affective or communicational aspects without necessarily
making them central to a theory [92,93].
Table 1 summarizes these seven dimensions.
Discussion
Any given case of participation can combine these seven
dimensions in different degrees - some will focus oneducation and voice, for instance, others on metrics and
an experience of collectivity. We have evaluated our 102
cases in order to determine what distribution of dimen-
sions occur across cases of widely different domains -
from free software and citizen journalism to science and
medicine to economic participation. Figure 3 summa-
rizes the evaluation of 14 of these cases that are catego-
rized as being in the domain of science or medicine in
our database. From even this subset, it is clear that there
is much diversity in the presence or absence of the seven
dimensions of participation listed here. Nearly all of the
cases have a strong commitment to education (dimen-
sion 1 in Table 1), but almost none of them seriously
consider allowing participants to be involved in agenda
setting (dimension 2). Control over resources (dimen-
sion 3) varies greatly, as does the relationship between
exit (dimension 4) and voice (dimension 5). But almost
all are committed to providing good metrics of partici-
pation, and about half are devoted to facilitating com-
munication or affective bonds between participants.
These 14 cases were selected here to exemplify the do-
main of science and medicine, but the same diversity ex-
ists in the larger set of 102 cases.
In order to describe in more detail what these findings
mean, we here examine several cases in more detail, in-
cluding two not in our database (because they precede the
advent of the Internet) but relevant to the issue of science
and medicine. The goal is to exemplify how these cases
combine different dimensions of participation; in the sum-
mary we propose some questions for thought and future
directions based on these evaluations.
AIDS activism (mid-1980s to mid-1990s)
Participation in medicine arguably received a huge boost
in the 1980s with the advent of AIDS and the activists
who engaged with the medical establishment. Although
this case is more clearly understood in the literature as a
case of a social movement [3,100], it inaugurated a wave
of patient advocacy and demands for greater inclusion
[70,71,101] that has continued into the present day.
These concerns now structure approaches to access to
medicine, clinical trials, and agenda-setting in research
[75,102]. AIDS activism in the 1980s exemplifies several
of the dimensions of participation laid out here. By be-
coming engaged, AIDS activists educated themselves
about everything from the process of science to the biol-
ogy of AIDS, and through that participation learned how
to engage the medical establishment in order to partici-
pate in the setting of goals as well as tasks. Although the
struggle could be conceived as one of resources, the
concern was less with direct control and more with in-
fluence over the outcomes of decision-making. Exit was
eschewed in favor of voice - speaking out and protesting.
But perhaps most significantly, the experience of AIDS
Table 1 Summary of seven dimensions of participation
Dimensions Description Representative
scholarly literature
Contemporary cases that exemplify
the participatory dimension
Strong Weak
1. Educative dividend Learning something valuable, especially
learning how to participate effectively
[54,78,94] Zooniverse, 23andMe Match.com, BOINC
2. Goals and tasks Participants not only undertake tasks





3. Resource control Participants get to control (own or use)
resources, not merely produce them
[65,96-99] Second life; Mukurtu;
SNPpedia
Patients Like Me
4. Exit Capacity to leave without penalty and
with resources
[79] Global Voices; SNPpedia Facebook
5. Voice Opportunities to 'speak back' in order
to influence outcomes
[79,80] Wikipedia; Apache OKCupid
6. Visible metrics Empirical demonstrations of the connection
between participation and outcomes
[56,85,90] Foldit; 23andMe Revision 3
7. Affective/communicative
capacity
Participants have opportunities to
communicate amongst themselves to
produce affect, affiliation, and sociability
[91-93] Instagram; PXE international;
Patients Like Me
Bitcoin
Summary of seven dimensions of participation.
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others in a new way, and created a collective experience
that defined a generation, created lasting bonds, and cre-
ated new professional and personal possibilities.
PXE International (1995 to now)
PXE International, a patient advocacy group represent-
ing those with pseudoxanthoma elasticum (a rare genetic
disorder that mineralizes elastic tissues in certain parts
of the body), was founded in 1995 by Sharon and Patrick
Terry because of their frustration with the pace and
disorganization of research into PXE, which afflicted
their children [103]. PXE International is well known for
its active role in initiating and organizing research, not
just organizing patients and advocating on their behalf
or funding scientists at a distance [104]. Though lacking
science training, the Terrys participated actively in the
laboratory research that would lead to the discovery of
the mutation responsible for PXE, and the scientists they
worked with agreed to assign rights to the gene patent
to the organization. PXE International has served as a
model for other advocacy groups seeking to form them-
selves as research organizations [18,105,106].
We can see that PXE International includes many, if
not all, of the dimensions of participation. Disease suf-
ferers, and especially those with rare diseases, often suf-
fer from social isolation and alienation in addition to
physical disease effects. Advocacy organizations help
give disenfranchised individuals voice and they connect
them into networks of affect and mutual support. PXE
International has had a trebly effective educative divi-
dend: patient participants learn about PXE and how
to deal with it, scientific knowledge about PXE has
expanded through the organization’s activities, andparticipants - both scientists and advocates - have
learned how to engage each other, to participate to-
gether, more effectively. The organization has made part
of its mission educating other organizations how to rep-
licate their successes. Unlike the traditional advocacy
model where lay people participate in research by being
research subjects and having limited effect on the goals
of research other than by sponsoring certain projects (or
asking politicians to sponsor them), PXE International
members have directly interacted with scientists and
work in partnership with them to decide which research
directions to pursue. Further, their control of resources
is substantial: beyond the patent to the ABCC6 muta-
tions causing the disease, PXE International has built
and maintained an important biobank of patient samples
and data, and they use these to attract researchers,
enforce cooperative relations among them, and steer
the course of their work. PXE International as a collect-
ive entity is nearly an ideal type of the participatory
organization by our dimensions. While this is true at the
collective/organizational level, we often think of partici-
pation in individual terms, and the experience of the
average individual participant may not be the same as
this collective story of success.
Patients Like Me (2004 to now)
Patients Like Me provides a particularly striking case of
participation in medicine enabled by the Internet and
social media. Begun in 2004, the website is devoted to
bringing patients together outside of conventional chan-
nels of either formal medicine or support groups and pa-
tient organizations. Patients can sign up and share
information about their condition with others, including
extremely detailed daily or hourly reports on treatment,
Figure 3 Results for science/engineering/medicine cases. Fourteen cases of participation in the domain of science engineering and medicine.
Question numbers correspond to the domains in the 'Background' section; cases are ordered by the total evaluation ('summary') at right.
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and interests to drugs and treatments taken, to side ef-
fects and related conditions can and often are reported.
Patients can message each other, 'follow' each other and
offer support in ways that are similar to other social
media sites [107].
Patients Like Me clearly has strong educative potential,
effectively uses metrics to display individual and collect-
ive participation, and promotes strong affective and
communicational bonds amongst users. The value for
patients is clearly in the creation of new relationships,
knowledge sharing and learning about treatment and the
experience of a disease. Patients get out of it what they
put in, and have access to a potentially much larger pool
of people in similar situations than they might otherwise.
The site is also very metric-driven: one can see not only
one’s own progress and change over time, but that of
others with similar conditions. The use of metrics can
be a very important feature in making visible the effects
of participation to all those involved, and Patients Like
Me is built on the visibility and comparability of such
metrics.
But on the flip side, the project does not facilitate
good resource control and participation in agenda-
setting. Patients Like Me makes money by selling the
data that patients provide - anonymized and tailored
for different clients, and they are honest about this
aspect of the business. But controlling the data one
provides is not something patients can do - either they
give up control or they must exit. Similarly, there is
no direct channel for patients to be involved in
decision-making, either about their own data, the
general decision about the choice of clients, or mar-
keting of the available data.
23andMe (2007 to now)
Though direct to consumer genetics is a growing sector,
23andMe is the best-known and most fully realized of
the efforts. For a small fee (currently $99), people can
send in a DNA sample that is sequenced with a single
nucleotide polymorphism (SNP) array. The resulting
data are presented in terms of the individual’s disease
risks, trait propensities, and biogeographic ancestry. So-
cial networking functions allow individuals to communi-
cate their traits with others and also to connect with
genetically identified possible relatives in the database.
Beyond the broader fact of gaining access to heretofore
exclusive information, the main participatory element
is that users are asked to fill out numerous surveys
about themselves. The information is used partially to
customize the individual’s risk profiles, but it is also the
basis of 23andMe’s research agenda, which has published
research on many physical traits, population genetics,
and Parkinson’s disease [35,108-110].On November 25, 2013 the FDA told 23andMe to stop
selling genetic tests arguing that they comprised a medical
device providing medical interpretations that had not been
validated and approved by regulators. This action reflects,
in part, a conflict about public participation in science.
23andMe wants to encourage participation in the world of
biomedical information; give people information and let
them do what they want. The FDA, in contrast, is asserting
a more traditional elite-driven model; information must be
controlled and validated by experts before the public may
have access to it. 23andMe is implicitly in the business of
'disrupting' the existing regime, but its authority must still
be respected.
The educative dividend of participating in 23andMe is
clear; participants learn about genetics in general and
their own genetic background in particular (though how
an individual should interpret these data is ambiguous).
There are also clear metrics of participation - the site re-
minds users how many surveys they have filled out and
prompts them to fill out additional ones. However, par-
ticipation in the goals is limited. Occasionally users are
polled on which research project 23andMe should pur-
sue, but more robust agenda setting is denied. Users are
allowed to access their risk profiles and download their
genetic data, but by agreeing to participate users grant
23andMe ownership, control, and discretion about shar-
ing the genetic and survey data even after a participant
leaves. User participation is governed by an institutional
review board, and there is a procedure for withdrawing,
but it is unclear what happens to data that have been
shared extramurally with research partners. Thus, the
option of exit is ambiguous. Finally, via social network-
ing functions, 23andMe allows some affective connec-
tion and communication - notably among previously
unknown 'relatives'. Communication among users and
talking back to the organization are features facilitated
by the site’s blog and comment system.
At first glance, these affordances (entirely typical
among such websites) do not seem to be structured to
enable much voice for users about the conduct of the
organization. Yet, when 23andMe announced a patent
for genetic variations associated with Parkinson’s disease,
these became the venue of a heated protest by partici-
pants. Two points are relevant here. First, that even a
participatory dimension whose affordances do not ap-
pear that radical (comment fields are ubiquitous) can
still enable participant revolt. Second, the controversy
overall reflects conflict over the 'ownership and control'
dimension discussed above. For protestors, the patent
belied the company’s ethos of openness and sharing.
Where their participation had been portrayed as a re-
search partnership, suddenly 23andMe’s commercial
character came to the fore and participants were re-
vealed to be (in part) resources to be mined.
Kelty and Panofsky Genome Medicine 2014, 6:8 Page 11 of 14
http://genomemedicine.com/content/6/1/8SNPedia (2006 to now)
SNPedia is an online wiki that allows users to interpret
their own genetic SNP data using publicly available asso-
ciations with particular SNPs [111]. The site is partnered
with a piece of software called Promethease that connects
an individual’s SNP data to the wiki. Whereas 23andMe
offers users a processed version of this information, using
proprietary algorithms to weight research findings and
produce a personalized risk estimate, SNPedia provides
do-it-yourself users the raw information. This information
is more varied, voluminous, and detailed; it offers users
the opportunity to make their own evaluations about risk
but also to pursue information about the actual mo-
lecular biology in the published literature that may be
behind a given SNP association. In addition to using
the resource to interpret their own genetic data, users
can participate by updating the wiki (linking SNPs to
published findings and offering their own annotations).
SNPedia contrasts with 23andMe and the Personal
Genome Project in that it does not ask for users’ DNA
information for its own purposes; it is only a resource
by which users can interpret their own data. It does
have an implicit relationship with those sites, however,
because SNPedia does not offer users a way to sequence
their data, they must bring their own, and 23andMe
and PGP are two common sources [112].
Once potential users overcome the significant barrier
of acquiring their genetic data, they can reap a signifi-
cant educational dividend from using SNPedia. The in-
formation is not for casual users in that they have to be
willing to interpret and explore information that is
much closer to the scientific literature and less stan-
dardized than 23andMe, for example. Yet they have the
opportunity to explore more of the current state of the
art. Since SNPedia has few goals and tasks outside the
resource itself, there is relatively little opportunity to
participate in this regard. There are no metrics of par-
ticipation apart from the links between genetic data and
the information in the wiki. And opportunities to speak
back to the entity and affect its course are primarily
achieved by sending emails to the project’s leader,
Michael Cariaso. Thus, voice and goal influence are
largely informal, and occur at his discretion. Under a
Creative Commons license, users have access to the re-
source without paying and they maintain control of
their genetic data without ceding it to the organization.
Thus, participants have full capacity for exit. In contrast
to other entities where full participation must be con-
trolled for the purposes of pursuing profit or an autono-
mous research agenda, in SNPedia there is very full
participation along certain dimensions and those di-
mensions where it is lacking are due to the limited am-
bitions and informality of the enterprise, not active
efforts at control.Conclusion/summary
The cases presented above are intended to exemplify the
different dimensions of participation, and to demon-
strate how different kinds of participation can be at stake
in different projects. On the basis of this diversity, it is
possible to conclude that different styles or modes of
participation emphasize or de-emphasize different as-
pects, and that an empirical analysis might reveal the
distribution of these styles of participation and poten-
tially their efficacy or outcomes as well. At an empirical
level one can ask what the 'signature' of participation is
by looking at more than just one dimension. From this
perspective, the relatively narrow concern with patient
participation in treatment decisions concerns only a sin-
gle dimension, whereas a case like PXE engages all of
them. This is an implicitly normative claim, to be sure,
but it also points the way towards understanding distinct
advantages or disadvantages that might be associated
with one or another signature of participation.
Indeed, there are multiple ways to both succeed and to
fail at participation - and when it does not work, it is
not necessarily 'participation' in an abstract sense that
fails. Does participation need to have all seven dimen-
sions? Which signatures are good for what reasons?
Good for improving individual and public health? Good
for introducing efficiency or profitability into healthcare
or scientific research? Good for innovation or discovery?
These are questions that cannot be assessed without a
more robust model or theory of participation. On the
basis of these dimensions we can hypothesize the mode
of participation that results from the emphasis on one
or another dimension. Facebook, for instance, empha-
sizes the collective experience and the use of metrics to
display the social network to its users, but deempha-
sizes control over resources or access to goals. As such
it can be labeled a more 'extractive' form of participa-
tion, focused on transforming resources valuable to
one group (users) into resources valuable to another
(advertisers). Conversely, projects like Wikipedia, which
emphasize the first five dimensions, but are less inter-
ested in displaying or facilitating a feeling of participa-
tion, are more 'volatile' and unstable - committed to
openness but struggling with sustainability; open to all
comers, but not necessarily 'user-friendly'. In the do-
main of genomics, 23andMe clearly looks more like the
former, and SNPedia like the latter (and this is no his-
torical accident).
Similarly, a case like PXE, with its emphasis on nearly
all the dimensions, is less intensely focused on the indi-
vidual’s own responsibility for (and freedom to) monitor
and understand his or her own health - and more ori-
ented towards the production of community and collect-
ive control and power. When participation is understood
primarily as a form of consumption (giving individuals
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tients or collectives), then its signature is of one type,
and with the framework above, it might be possible to
both identify such instances, and ask 'what choices about
the design or management of a project can shift it more
in the direction of one signature than another?'
With scientific institutions being more exposed to
public scrutiny and bearing more of a burden to justify
themselves not just to authorities but to the citizenry
that supports them, accommodating public participation
will become more of an obligation for scientists. This is
an emerging obligation that carries considerable risks in
terms of loss of control and rise of contention in the re-
search process. Yet it also offers many intriguing possi-
bilities for new forms of collaboration, data, knowledge
production, funding, and serving public needs.
So what lessons can a clinical scientist, genomics re-
searcher or entrepreneur draw from this analysis? As we
have shown, public participation is much more compli-
cated and multidimensional than it is usually taken it to
be. It is more than simply enrolling participants and tell-
ing them what to do; at least, participants today tend to
expect much more than that. When seeking to engage
public participation in their research, scientists would do
well to think about the dimensions we have identified
and consider the synergies and trade-offs among them.
Scientists would seem to be most comfortable with the
educative, task, metrical, and community dimensions of
participation. But participants themselves often want
more. They want influence over goals, they want to
share in the benefits of the resources created, they want
genuine opportunities to engage scientists without too
many barriers of expertise and authority. These are
among the lessons of the brief case studies presented
above. What scientists might realize is that scientific au-
thority and knowledge production are not necessarily
zero sum games. As the PXE International example and
many other cases of patient advocacy in genetic research
show, close participation can produce synergies and en-
ergies that catapult basic and clinical science forward
[106]. New productive equilibria can be reached that are
superior to whatever degree of authority scientists cede
to participants.
Finally, it has long been a key feature of the literature
on participation that participation is inherently political -
meaning that it is about the redistribution of resources
and the struggle for power over decision-making. But it
is also about collective experience and the feeling of be-
ing a part of something larger. While incorporating
strong forms of participation may therefore come with
risks - that doctors might have less claim to expertise, or
that companies might have less control over the circula-
tion of data - it also comes with benefits that far exceed
the immediate domain of patient care or research: it cancreate patterns of authority and responsibility that influ-
ence other aspects of social and political life beyond that
of medicine.
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